United Kingdom Colorectal Cancer Therapeutics Market By Drug Class (Chemotherapy, Immunotherapy, Others), By End User (Hospitals, Clinics, Others), By Region, Competition Forecast & Opportunities, 2018-2028F

The United Kingdom Colorectal Cancer Therapeutics Market is expected to witness significant growth during the projected period of 2028. Colorectal cancer, a prevalent public health concern in the United Kingdom, affects the colon or rectum. However, thanks to the country's robust healthcare system and dedicated research and development efforts, advancements in colorectal cancer therapeutics have been achieved. The United Kingdom's colorectal cancer therapeutics market has experienced substantial growth, driven by innovative treatments, targeted therapies, and early detection methods that have revolutionized patient care and improved survival rates.

Colorectal cancer typically originates in the colon (large intestine), where abnormal growths or polyps in the inner lining can lead to the development of cancer. Precancerous polyps can be identified through screening tests performed by healthcare professionals before they progress into cancerous tumors. Timely diagnosis and treatment of colorectal cancer are crucial to prevent its spread to other parts of the body. Fortunately, the implementation of screening tests, early treatment, and innovative therapies has resulted in fewer deaths from colorectal cancer. The United Kingdom's colorectal cancer therapeutics market has witnessed the introduction of various innovative therapies aimed at providing better outcomes and improving patients' quality of life. Notably, targeted therapies have garnered significant attention. By focusing on specific molecular and genetic abnormalities present in cancer cells, targeted therapies offer more precise and effective treatments. Monoclonal antibodies and small molecule inhibitors are examples of such therapies, which have shown promise in improving survival rates and reducing the side effects associated with traditional chemotherapy.

According to the Office for National Statistics, the healthcare cost in the United Kingdom was estimated to be approximately USD350.83 billion in 2022, representing a nominal increase of 0.7% compared to 2021.

Rising Prevalence of Colorectal Cancer Will Spur the Demand for Colorectal Cancer Therapeutics

The United Kingdom is facing a significant burden of colorectal cancer, a devastating disease that claims numerous lives each year. According to the UK Colorectal Cancer Intelligence Hub, colorectal cancer affects over 41,000 people annually in the United Kingdom, with 16,000 deaths resulting from it. The incidence of colorectal cancer has been steadily increasing over the past few decades, attributed to factors such as sedentary lifestyles, unhealthy dietary habits, obesity, and an aging population. Colorectal cancer arises when cells undergo uncontrolled growth and division, similar to other types of cancer. Normally, the body's cells continuously divide, grow, and die, maintaining overall health and functionality. However, in colon cancer, the cells lining the colon and rectum continue to grow and divide instead of dying as they should. These cancerous cells may originate from colon polyps. Improved screening methods and increased awareness have led to early detection, resulting in a higher number of reported cases and expanding the United Kingdom Colorectal Cancer Therapeutics Market. The rising prevalence of colorectal cancer has driven the development and advancement of various treatment modalities within the market, including surgery, radiation therapy, chemotherapy, targeted therapies, immunotherapies, and supportive care. Targeted therapies and immunotherapies, such as monoclonal antibodies and immune checkpoint inhibitors, have revolutionized the treatment landscape by offering more personalized and effective options. Precision medicine has gained significant momentum in the field of colorectal cancer treatment, enabling clinicians to identify specific biomarkers that determine a patient's response to certain therapies through molecular profiling and genetic testing techniques. This approach allows for tailored treatment plans, minimizing unnecessary side effects and optimizing therapeutic outcomes. The increasing availability and affordability of genomic profiling technologies have further facilitated the adoption of precision medicine in the management of colorectal cancer, thereby driving the anticipated growth of the United Kingdom Colorectal Cancer Therapeutics Market in the forecast period.

Rising Geriatric Population Drives the United Kingdom Colorectal Cancer Therapeutics Market

The United Kingdom is currently undergoing a significant demographic shift, characterized by a rapidly aging population. With the number of elderly individuals on the rise, the prevalence of age-related diseases, such as colorectal cancer, is also increasing. This demographic trend has far-reaching implications for the healthcare system, particularly in the field of cancer therapeutics. The United Kingdom Colorectal Cancer Therapeutics Market is experiencing substantial growth, driven by the growing geriatric population and the subsequent demand for effective treatment options. According to the Organization for Economic Co-operation and Development (OECD), the proportion of elderly people in the total population of the United Kingdom is 18.83%. The geriatric population is particularly susceptible to developing colorectal cancer due to various factors, including age-related changes in the digestive system, genetic predisposition, and lifestyle choices. Consequently, there is an urgent need for advanced therapeutics to effectively treat colorectal cancer and improve patient outcomes. This demand has prompted extensive research and development activities in the pharmaceutical industry, leading to the introduction of innovative treatment options. The United Kingdom Colorectal Cancer Therapeutics Market encompasses a wide range of therapies, including surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Surgical interventions remain the primary treatment option for localized colorectal cancer, aiming to remove the tumor and affected tissues. However, for advanced stages of the disease, a multidisciplinary approach involving chemotherapy and radiation therapy is often employed. Furthermore, the increasing geriatric population has necessitated greater investment in healthcare infrastructure and research initiatives. Government bodies and healthcare organizations are actively supporting clinical trials and research studies to enhance the understanding of colorectal cancer and develop new treatment modalities. This collaborative effort between academia, industry, and healthcare providers is crucial in advancing the field of colorectal cancer therapeutics and improving patient outcomes. Additionally, the growing awareness of colorectal cancer and the demand for improved therapeutics have fostered collaborations among researchers, pharmaceutical companies, and healthcare providers. These partnerships have accelerated the development of innovative treatment options and facilitated access to advanced therapies for patients. By leveraging collective expertise and resources, these collaborations are driving progress in the fight against colorectal cancer, thereby bolstering the growth of the United Kingdom Colorectal Cancer Therapeutics Market. As reported by the Office for National Statistics, the statistical results for 2021 indicate that the population of England and Wales continues to age, with a notable increase in the number of individuals in older age categories. Nearly 11 million people, or 18.6% of the total population, are now 65 years of age or older, compared to 16.4% during the previous census in 2011. Among this group, there are 527,900 individuals who are at least 90 years old.

Recent Developments

• According to the results of a clinical trial funded by Cancer Research UK and conducted by the Universities of Birmingham and Leeds in March 2023, administering chemotherapy to colon cancer patients before surgery has been shown to decrease the likelihood of disease recurrence. The FOxTROT trial revealed that administering the first six weeks of chemotherapy prior to surgery, as opposed to after, reduces the risk of cancer recurrence within two years by 28%.

Mergers and Acquisitions

• In October 2022, a clinical trial partnership and supply agreement between Erasca and Pfizer focused on Palbociclib (Ibrance), a CDK4/6 inhibitor. The aim is to address colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) with KRAS- and NRAS-mutations, through a clinical proof-of-concept trial using ERAS-007 in combination with Palbociclib.
• Furthermore, in March 2023, Pfizer allocated USD43 billion for the acquisition of Seagen, thereby expanding its capabilities in cancer treatment.
• Additionally, in August 2022, Eli Lilly & Company collaborated with ERASCA to investigate the combination of ERAS-601 and Cetuximab for the treatment of metastatic colorectal cancer.

Market Segmentation

United Kingdom Colorectal Cancer Therapeutics Market is segmented into Drug Class, End User, Region and Competitive Landscape. Based on Drug Class, the Market is divided into Chemotherapy, Immunotherapy and Others. Based on End User, the market is categorized into Hospitals, Clinics and Others. Based on region, the United Kingdom Colorectal Cancer Therapeutics Market is segmented into Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands.

Company Profiles

Novartis AG, Pfizer Inc, Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eisai Co., Ltd., Sanofi S.A., Roche Holding AG are some of the key players in the United Kingdom Colorectal Cancer Therapeutics market.

Download Free Sample Report

Report Scope:

In this report, United Kingdom Colorectal Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

• United Kingdom Colorectal Cancer Therapeutics Market, By Drug Class:
• Chemotherapy
• Immunotherapy
• Others
• United Kingdom Colorectal Cancer Therapeutics Market, By End User:
•  Hospitals
• Clinics
• Others
• United Kingdom Colorectal Cancer Therapeutics Market, By Region:
• Scotland
• South-East
• London
• South-West
• East-Anglia
• Yorkshire & Humberside
• East Midlands

Competitive landscape

Company Profiles: Detailed analysis of the major companies in United Kingdom Colorectal Cancer Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).